Genor Biopharma Holdings Ltd. has provided an update on its proposed merger, which involves the issuance of consideration shares under a specific mandate. The company also mentioned a reverse takeover and a new listing application. Additionally, there are plans for a change of company name and an increase in authorized share capital. The proposal includes the adoption of a one-off share option plan. The transaction is contingent upon certain conditions, including the granting of a whitewash waiver. The merger's finalization remains conditional on meeting these prerequisites.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。